Treatment Facility: An Important Prognostic Factor for Dedifferentiated Liposarcoma Survival
- PMID: 31507311
- PMCID: PMC6719806
Treatment Facility: An Important Prognostic Factor for Dedifferentiated Liposarcoma Survival
Abstract
A National Cancer Database study of on survival outcomes for patients with dedifferentiated liposarcomas found that insurance status, median household income, and treatment facility were associated with differences in median survival and 5- and 10-year survival probabilities.
Conflict of interest statement
Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
Figures





Similar articles
-
Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.Am J Surg Pathol. 1997 Mar;21(3):271-81. doi: 10.1097/00000478-199703000-00002. Am J Surg Pathol. 1997. PMID: 9060596
-
Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.Hum Pathol. 2017 Aug;66:86-92. doi: 10.1016/j.humpath.2017.02.015. Epub 2017 Mar 12. Hum Pathol. 2017. PMID: 28300575
-
Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas.Int J Cancer. 2002 May 1;99(1):68-73. doi: 10.1002/ijc.10287. Int J Cancer. 2002. PMID: 11948494
-
Managing Liposarcomas: Cutting Through the Fat.J Oncol Pract. 2016 Mar;12(3):221-7. doi: 10.1200/JOP.2015.009860. J Oncol Pract. 2016. PMID: 26962163 Review.
-
Primary Orbital Dedifferentiated Liposarcoma.World Neurosurg. 2020 Jul;139:604-607. doi: 10.1016/j.wneu.2020.04.069. Epub 2020 Apr 25. World Neurosurg. 2020. PMID: 32339743 Review.
Cited by
-
Transmediastinal primary pulmonary liposarcoma: Case report and review of management strategies.Rare Tumors. 2024 Aug 11;16:20363613241274230. doi: 10.1177/20363613241274230. eCollection 2024. Rare Tumors. 2024. PMID: 39139396 Free PMC article.
-
Myogenic dedifferentiation is associated with poor outcomes in retroperitoneal dedifferentiated liposarcomas.Rare Tumors. 2021 Feb 26;13:2036361320986655. doi: 10.1177/2036361320986655. eCollection 2021. Rare Tumors. 2021. PMID: 33738084 Free PMC article.
-
Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma.Front Oncol. 2025 Mar 17;15:1489833. doi: 10.3389/fonc.2025.1489833. eCollection 2025. Front Oncol. 2025. PMID: 40165894 Free PMC article.
-
Molecular docking and biological evaluation of a novel IWS1 inhibitor for the treatment of human retroperitoneal liposarcoma.Sci Rep. 2025 Jul 2;15(1):22965. doi: 10.1038/s41598-025-07215-y. Sci Rep. 2025. PMID: 40594510 Free PMC article.
-
Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.Noncoding RNA Res. 2024 Nov 15;11:73-90. doi: 10.1016/j.ncrna.2024.11.005. eCollection 2025 Apr. Noncoding RNA Res. 2024. PMID: 39736850 Free PMC article. Review.
References
-
- Dodd LG. Update on liposarcoma: a review for cytopathologists. Diagn Cytopathol. 2012;40(12):1122–1131. - PubMed
-
- Mangham D. World Health Organisation classification of tumours: pathology and genetics of tumours of soft tissue and bone. J Bone Joint Surg Am. 2004;86(3):466.
-
- Coindre JM, Pédeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010;456(2):167–179. - PubMed
-
- Evans HL. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979;3(6):507–523. - PubMed
LinkOut - more resources
Full Text Sources